We want to bring attention to some significant unsolved issues. Frequency of this new mutation in AML population is unknown at present, since all large studies where NPM1 mutations were determined only involved exon 12 amplification from genomic DNA or use of specific probes for known mutations precluding exon 11 region [4] [5] [6] [7] (see references cited in Mrozek et al . 1 ), which let in all cases this new truncation mutation go unnoticed. Even recommended immunohistochemical determinations 2 may have failed detecting this alteration, due to its mixed staining pattern. New analyses of the thousands of samples available in large leukaemia study groups would allow to obtain the frequency for this new type of NPM1 mutation, thus opening the possibility of redefining new subclasses of AML-NK based in these molecular findings. At this point, it is interesting to add that in their recent review 2 Falini et al. mentioned an abstract where the presence of an exon 11 mutation in an AML patient is described (Albiero et al. Haematologica 2006; 91: 237, abstract). The reported mutation at exon 11 is the same kind of eight nucleotide insertion as the one we have found and reported here, but the inserted nucleotides are different in sequence, although both alterations produce a similar truncated protein. These data reinforce the possibility that a new hot spot for insertional mutation in NPM1 might have been located and strengthen the need for establishing the frequency of this type of mutation in AML patients as well as the biological consequences of this new finding. 1 2 This is mainly due to the fact that fresh cells are usually not available for cytogenetic and/ or molecular studies. In fact, the diagnosis of MS is frequently unexpected and/or the size of the sample is small, such as a skin punch biopsy. Since MS is usually treated in the same way as AML, the frequent lack of available cytogenetics in MS represents a significant disadvantage, and the availability of techniques applicable to paraffin samples to detect specific genetic lesions would be of great help both for diagnostic and prognostic purposes.
Nucleophosmin (NPM) 1 mutations with consequent aberrant cytoplasmic expression of NPM 3, 4 represent the most common genetic abnormality in AML, but no information is available on the role of NPM in MS. Since immunohistochemical detection of cytoplasmic NPM in AML predicts NPM1 mutations, 5 we used anti-NPM antibodies 4 to detect cytoplasmic/mutated NPM in 181 paraffin-embedded MS samples (characteristics of these cases are provided in the Supplementary Information). Immunohistochemical results were confirmed in a subset of cases by a PCR assay that we developed for application on formalin-fixed samples. We found 26 NPMc þ MS, whose biological and clinical features are reported here.
The 181 MS samples were first immunostained with the monoclonal antibody (mAb) 376 (recognizing both wild-type and mutated NPM proteins) (Supplementary Information). Immunostaining results were evaluable in 173/181 MS cases; in eight cases, they were difficult to interpret because of the small size of tissue samples, shrinkage artefacts and/or antigenic denaturation of the NPM protein. In 147/173 cases (85.0%), NPM showed a nucleus-restricted expression that was identical to nucleolin (C23) (Figure 1 ). This staining pattern is known to predict absence of NPM1 mutations, as reported previously in AML. 5 In 26/173 cases (15.0%), aberrant cytoplasmic NPM expression was detected ( Figure 2 ; Table 1 ), a staining pattern that is known to predict NPM1 mutations. 5 The leukaemic cells from these cases also showed nuclear NPM positivity (Figure 2 ), due to the residual NPM wild-type protein in the nucleus. 4 All NPMc þ MS cases showed the expected nucleolin/C23 nucleusrestricted positivity ( Figure 2 ).
NPM1 mutations are consistently heterozygous; 3,4 therefore, leukaemic cells contain both wild-type and mutated NPM proteins. Anti-NPM mAb 376 cannot discriminate between these two types of proteins. 4 To confirm that in MS samples, cytoplasmic NPM dislocation is the consequence of NPM1 mutations, we stained paraffin sections by the alkaline phosphatase anti-alkaline phosphatase (APAAP) technique using polyclonal antibodies (Sil-A and Sil-C) that specifically recognize NPM mutant proteins (Supplementary Information). Immunostaining was performed on 18/26 NPMc þ MS samples for which a sufficient amount of paraffin-embedded material was available for analysis. Antigenicity of NPM mutant proteins was preserved in 14/18 immunostained cases. Paraffin sections from 15 NPM cytoplasmic-negative (NPMcÀ) MS specimens served as negative controls. In the 14 NPMc þ MS samples, where antigenicity was preserved, expression of NPM mutant protein was consistently cytoplasmic-restricted ( Figure 3 ). This is in keeping with previous findings in NPMc þ AML, 4 and with the observation that, in transfected cells, NPM mutant constructs localize exclusively in the cytoplasm. 4 With one exception, none of the NPMcÀ MS reacted with Sil-A and Sil-C. The discrepant case was included in the subset of cases, which were subjected to PCR sequence analysis (see below).
To confirm further that subcellular NPM immunostaining pattern in MS samples predicts NPM1 gene mutations, a PCR assay was designed that is suitable for application on RNA extracted from formalin-fixed paraffin-embedded samples (FFPE) (technical details are given in the Supplementary Information). We selected 16 MS samples for the analysis (7 NPMc þ , 9 NPMcÀ). An evaluable PCR product was obtained in 12/16 cases investigated (5 NPMc þ , 7 NPMcÀ) ( Table 2 ). In 11/12 of these cases (5 NPMc þ , 6 NPMcÀ) the aberrant cytoplasmic localization of NPM correlated with the presence or absence of NPM1 mutations (Table 2 ); in one case (case 6) the result was Letters to the Editor discrepant. This case scored nuclear (NPMcÀ) with clone 376 but cytoplasmic with Sil-A and Sil-C antibodies ( Table 2 ). The PCR assay revealed a mutated sequence, indicating that the immunostaining for mutated NPM predicted the mutations correctly (Table 2) . Possibly, in this particular case, the epitope recognized by mAb 376 on wild-type NPM was better preserved than that recognized by sil-A and sil-C in mutated NPM, thus explaining the nucleus-restricted positivity that in NPMc þ AML is mostly accounted by the residual wild-type NPM. 4 Comparison of the mutated sequences found in this study to published data, showed that five cases harbored the NPM1 type A allele 3 and one case contained the Km allele. 6 The clinicopathological and cytogenetic features of the 26 NPMc þ MS are shown in Table 1 . The male/female ratio was 1.00, similar to the NPMcÀ cases (1.03). Mean age of patients was 62.2 years (range 11-86) not significantly different from NPMcÀ cases (mean age 55.6 years, range 11-86). The most frequently involved sites were skin and lymph nodes; other extramedullary sites were involved less frequently (Table 1) . In 24 patients, the tumor was localized; one patient ( Skin involvement 20 years after the initial diagnosis of AML. 7 None of the cases was preceded by a chronic myeloproliferative disorder or myelodisplastic syndrome. Clinical and pathological data were available in 126 out of the 147 NPMcÀ MS samples (Supplementary Table) . The NPMcÀ and NPMc þ MS cases clearly differed in respect to a previous chronic myeloproliferative disorder or a myelodysplastic syndrome (39.6% in NPMcÀ vs 0% in NPMc þ , 0.001) and the frequency of cases showing CD34 positivity (12% in NPMcÀ vs 47.85% in NPMc þ , Po0.001). Moreover, NPMcÀ MS cases showed a higher frequency of cytogenetic abnormalities, as only 4/21 patients (19%) for whom cytogenetics was available had normal karyotype, vs 6/7 NPMc þ cases (85.7%) (Po0.001). The 17 NPMcÀ MS cases with an abnormal karyotype (81%) showed the following cytogenetic abnormalities: t(8;21)(q22;q22) (n ¼ 3); t(9;22)(q34;q11.2) (n ¼ 3 chronic myeloid leukaemia in transformation); t(15;17)(q22;q21) (n ¼ 1); 47,XX, þ 5, t(8;21)(q22;q22) (n ¼ 1); 47XY,? þ 2, t(6;11),À12,? þ 21(n ¼ 1); 47,XX, þ 8 (n ¼ 1); 47,XX, þ 8, t(9;22)(q34;q11.2)14/ t(9;22)(q34;q11.2)4 (n ¼ 1 chronic myeloid leukaemia in transformation); 47,XX, t(2;5)(q35;q22), þ 8 (n ¼ 1); 46XX/ 46,XX, t(11;11)(p15;q22) (information on the number of mitosis analyzed is not available) (n ¼ 1); and complex karyotype (n ¼ 4). According to the method of Kaplan-Meier, the probability of the overall survival of the NPMcÀ MS cases was 0.089 at 2 years, not statistically different from the overall survival of the NPMc þ patients (median survival time 8 and 9 months respectively).
In this study, we used immunohistochemistry to search for aberrant cytoplasmic NPM expression in 181 MS samples and detected it in 15% of them. Immunohistochemistry can serve as a surrogate for molecular studies for detecting NPM1 mutations in MS in most instances. In the few remaining cases, where interpretation of immunohistochemistry is difficult because of shrinkage artefacts and/or poor antigen preservation, the mutational status of NPM1 gene can be assessed by PCR from the same biopsies. Thus, the combination of the two methods allows to overcome the lack of fresh material for diagnosis of MS.
Notably, our results identify NPM1 mutations as the most frequent molecular lesion so far reported in MS, defining the molecular status in 15% of cases. NPMc þ MS showed the same distinctive features as de novo NPMc þ AML, 3 that is, frequent association with M4 and M5 FAB categories, lack of CD34 expression and association with normal karyotype. The presence of trisomy 8 in one case concurs with previous observations that about 14% of NPMc þ AML carry minor chromosomal abnormalities, which are probably secondary events. 3, 4 As in NPMcÀ AML, 3 all MS cases carrying major genetic abnormalities, including t(8;21), MLL rearrangement, t(15;17) and complex karyotypes showed nucleus-restricted NPM expression, indicating the absence of NPM1 mutations. Nucleusrestricted NPM expression was also observed in all 24 MS cases, arising in a setting of myelodysplasia or a chronic myeloproliferative disorder, consistent with the finding that NPMc þ AML is usually a de novo leukaemia. 3 Our findings that NPMc þ MS progressing to AML as well as NPMc þ AML relapsing as MS maintained, in these different stages of the disease, the aberrant cytoplasmic expression of NPM is in keeping with the previous reported stability of NPM1 mutations. 8 In AML, NPM1 mutations in the absence of FLT3-ITD identify a subgroup of patients with favorable prognosis. 4, 6 In contrast, only 3/26 of NPMc þ MS patients are still alive. Several reasons may underlie this discrepancy. Because of lack of fresh material, information on FLT3 status is lacking in our patients. Advanced age is a known poor prognostic factor in AML; 15/26 patients with NPMc þ MS were older than 60 years. Treatment of patients in this series was very heterogeneous. Moreover, due to advanced age and delay in diagnosis, many patients underwent only radiotherapy or chemotherapy with one or two cytotoxic drugs.
Our results have important clinico-diagnostic implications. Morphologically, MS may be misdiagnosed as lymphoblastic or diffuse large-cell lymphoma or non-haematopoietic tumor. Immunophenotyping is mandatory for diagnosis 1 and the diagnostic panel usually include antibodies against myeloperoxidase, CD68, CD117, CD79a, CD3, glycophorin-A, CD61 and CD34. Our results clearly indicate that anti-NPM antibodies should be added to this panel as they predict NPM1 mutations. Our data also provide a rationale for a genetic-oriented classification of MS in the upcoming version of WHO classification. 1 Future efforts should integrate data on NPM1 and FLT3-ITD status, to determine in prospective studies whether MS carrying mutated NPM in the absence of FLT3-ITD also constitutes a more favorable prognostic category, as has been reported for de novo NPMc þ AML. 4, 6 Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Thrombosis can occur at any phase of essential thrombocythemia with JAK2 V617F mutation: a single institutional study in Japan The JAK2 V617F mutation is an activating kinase that is constitutively expressed in the vast majority of patients with polycythemia vera and approximately half of those with essential thrombocythemia (ET). 1 The significance of the association between JAK2 V617F mutation in ET and thrombosis is still controversial: we have shown that ET patients with JAK2
V617F had more frequent thrombotic episodes compared with those with wild-type JAK2, whereas the platelet count at the initial ET diagnosis did not differ between wild-type ET and JAK2 V617F -positive ET. 2 On the basis of this evidence, we retrospectively sought and evaluated thrombotic episodes in ET patients to obtain more insight into the risk factors of thrombosis in ET patients.
We used the JAK2 mutational status database in 49 patients with ET in our institute. The JAK2 V617F mutation was determined using by the semiquantitative sequence-specific primer single-molecule fluorescence detection (SSP-SMPD) assay. As reported previously, ET patients with JAK2 V617F showed a significantly higher incidence of thrombotic episodes (10/31 versus 1/18: P ¼ 0.0308), high leukocyte count (P ¼ 0.0092) and hemoglobin level (P ¼ 0.0044) than those with wild-type JAK2. 2 ET patients with thrombosis had higher hemoglobin (14.571.5 versus 13.371.5 g/dl: P ¼ 0.0283) at initial diagnosis, whereas no significant differences were noted in leukocyte count (P ¼ 0.140), hematocrit level (P ¼ 0.0801) or platelet count (P ¼ 0.0877) (Supplementary Information 1) . Of the ET patients with JAK2 V617F mutation (n ¼ 31), no significant differences were noted in hematologic parameters regardless of whether they developed thrombosis or not.
In ET patients followed for at least 1 year, we found 11 patients who suffered thrombosis (Table 1) : two patients at intermediate risk, and nine at high risk, according to the thrombotic risk. 3 Six ET cases were initially diagnosed by thrombosis, and the remaining five had thrombotic events during stable phase of the disease. Hematologic parameters at the time of initial ET diagnosis in these two groups did not significantly differ, including leukocyte count (P ¼ 0.2703), hemoglobin concentration (P ¼ 0.1306), hematocrit level (P ¼ 0.4472) or platelet count (P ¼ 0.9662). Except for one patient (JAK2_0050),
